1. Home
  2. GKOS vs VNO Comparison

GKOS vs VNO Comparison

Compare GKOS & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.17

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Logo Vornado Realty Trust

VNO

Vornado Realty Trust

HOLD

Current Price

$29.18

Market Cap

6.1B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
VNO
Founded
1998
1946
Country
US
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.1B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
VNO
Price
$116.17
$29.18
Analyst Decision
Strong Buy
Hold
Analyst Count
14
11
Target Price
$133.07
$36.82
AVG Volume (30 Days)
770.3K
2.2M
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
2.49%
EPS Growth
0.36
N/A
EPS
N/A
N/A
Revenue
$383,481,000.00
N/A
Revenue This Year
$23.29
N/A
Revenue Next Year
$27.74
$4.35
P/E Ratio
N/A
$7.08
Revenue Growth
21.85
N/A
52 Week Low
$73.16
$28.08
52 Week High
$142.50
$43.37

Technical Indicators

Market Signals
Indicator
GKOS
VNO
Relative Strength Index (RSI) 52.32 40.07
Support Level $103.55 $28.54
Resistance Level $121.70 $30.14
Average True Range (ATR) 5.70 1.41
MACD -0.23 -0.08
Stochastic Oscillator 63.83 24.49

Price Performance

Historical Comparison
GKOS
VNO

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About VNO Vornado Realty Trust

Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.

Share on Social Networks: